Pharmaceutical and biotech company Laurus Labs reported consolidated net profit for September quarter surged to ₹193.75 crore from ₹17.72 crore a year earlier on the back of improved show in both CDMO and generics segments besides low base year effect.
The manifold increase in net profit came as revenue from operations rose 35% to ₹1,653.47 crore (₹1,223.70 crore). The company has declared an interim dividend of ₹0.80 per equity share of ₹2.
Divisional revenue numbers showed CDMO revenue increased 53% to ₹518 crore (₹339 crore). Generics revenue rose 28% to ₹1,135 crore (₹885 crore) primarily driven by continued uptake in ARV volumes and supported by developed market supplies.
“Our Q2 reflects on-going expansion of CDMO business, supported by sustained growth in generics. We continue to maintain leadership position in ARVs and make encouraging progress in delivering important clinical and commercial programmes,” founder and CEO Satyanarayana Chava said.
$2 million investment
A strategic investment of $2 million has been made in Aarvik Therapeutics to have access to novel antibody-drug conjugates (ADC) technology and pipeline aimed at accelerating integrated ADC services, he said in a release.
The “strong Q2 performance was in line with expectations. Going ahead, we retain our focus to invest behind high value CDMO/CMO business opportunities to drive near and long-term growth…,” CFO V.V.Ravi Kumar said.
Published – October 23, 2025 09:30 pm IST
